Ontology highlight
ABSTRACT:
SUBMITTER: Wong NS
PROVIDER: S-EPMC4101887 | biostudies-other | 2011 Nov
REPOSITORIES: biostudies-other
Wong Nan Soon NS Meadows Kellen L KL Rosen Lee S LS Adjei Alex A AA Kaufmann Scott H SH Morse Michael A MA Petros William P WP Zhu Yali Y Statkevich Paul P Cutler David L DL Meyers Michael L ML Hurwitz Herbert I HI
Cancer investigation 20111101 9
We conducted a phase I study to assess safety, pharmacokinetics, pharmacodynamics, and activity of lonafarnib plus gemcitabine. Subjects received oral lonafarnib twice daily and gemcitabine on days 1, 8, and 15 every 28 days; multiple dose levels were explored. Lonafarnib had no apparent effect on gemcitabine PK. Mean lonafarnib half-life ranged from 4 to 7 hr; median T(max) values ranged from 4 to 8 hr. Two patients had partial response; seven patients had stable disease at least 6 months. Oral ...[more]